Top Markets
#1 Threshold Network Threshold Network +65.04%
#2 TENDIES TENDIES +64.30%
#3 Cash Cat Cash Cat +22.24%
#4 OSK OSK +15.86%
#5 Magma Finance Magma Finance +13.64%
#6 Ape and Pepe Ape and Pepe +13.59%
#7 Asteroid Shiba Asteroid Shiba +13.00%
#8 Falcon Finance Falcon Finance +12.81%
#9 Kite Kite +12.56%
#10 龙虾 (Lobster) 龙虾 (Lobster) +11.22%
Coin of the day
Threshold Network Threshold Network
Settings
Language
ENGLISH
Currency
USD
Theme
Windlas Biotech Limited Windlas Biotech Limited

Windlas Biotech Limited

WINDLAS
Rank in Stocks #17115
Windlas Biotech Limited functions as a comprehensive contract development and... Windlas Biotech Limited functions as a comprehensive contract development and manufacturing organization (CDMO). Its CDMO offerings span the full product lifecycle, encompassing initial discovery, subsequent development, licensing, and large-scale commercial production of various generic pharmaceutical and nutraceutical items. Through these services, it assists clients in bringing both established and innovative pharmaceutical and nutraceutical products to market, which are then sold under the clients' proprietary brand names. Beyond its CDMO segment, Windlas Biotech also develops and manufactures its own portfolio of domestic trade generics and over-the-counter (OTC) brands, catering to the nutritional, ayurvedic, wellness, and personal care sectors. These in-house products reach consumers via a dual distribution approach: traditional offline channels like distributors, stockists, retail pharmacies, and institutional tenders, alongside a robust online presence through various e-commerce platforms. The company's international reach extends through exports, primarily to markets such as Vietnam, Myanmar, Sri Lanka, Thailand, the Philippines, Cambodia, Fiji, Trinidad & Tobago, and South Africa. Established in 2001, Windlas Biotech is headquartered in Gurugram, India.
Share Price
$12.15
Market Cap
$257.09M
Change (1 day)
10.00%
Change (1 year)
9.99%
Country
IN
Trade Windlas Biotech Limited (WINDLAS)

Category

Healthcare
P/E ratio for Windlas Biotech Limited (WINDLAS)
P/E ratio as of 2026 TTM: 0
According to Windlas Biotech Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Windlas Biotech Limited from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 38.38 -
IN
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.